Powerful journalism on tap - Download The Kashmir Monitor app.

Centre to ask Johnson & Johnson to pay up in hip implants case

Mumbai :Stung by criticism over inaction against Johnson & Johnson (J&J) in cases involving faulty hip implants, the government is launching a mammoth exercise to identify the affected patients across the country and ensure they receive compensation, which might run into tens of millions of rupees.
Once the patients are identified, the government will decide on the quantum of compensation in each case and then approach J&J for claim settlement. “In the worst case scenario, if J&J does not honour the compensation claims, the government might sue the firm in public interest under the Code of Criminal Procedure (CrPC),” a senior official said, requesting not to be named.
While a total of 4,700 surgeries were conducted in India using J&J subsidiary DePuy’s ASR hip replacement system, only 882 patients (accounting for 1,056 implants) could be traced through the ASR Helpline. DePuy set up a helpline and initiated the reimbursement process for ASR patients in India through Puri Crawford, insurance surveyors and loss assessors, in September 2010.
“The main task at hand is to identify the affected patients and then determine the degree of compensation. We plan to have regional committees (with help from the state food and drug commissioners), which will identify the affected patients in their region and then refer to the central committee,” a source said.
The regional committees would advertise in leading newspapers, alerting the patients about the process, the source added.
Eligible patients will be screened by conducting tests (cost of which would be borne by J&J) to determine the degree of disability. The report of individual patients will be submitted to the central expert committee, which will review it to determine the quantum of compensation.
“The compensation will be determined based on the degree of disability and the impact on one’s ability to lead a normal life and earn a livelihood. On a case-to-case basis, it can vary from Rs 2 million to tens of millions,” said the official.
The base amount (Rs 2 million) is such that if the affected patient keeps the amount of compensation in a bank by way of fixed deposit, at an interest of 7 per cent annually, he or she will get a monthly interest amount at least equivalent to the minimum wages. For example, the minimum monthly wage of an unskilled worker based in Delhi as of March 2017 was Rs 13,350. To earn this, a deposit of over Rs 2 million would be required to be kept in a bank account.
The central committee will also consider patients suffering on account of monetary loss due to loss of wages and other losses.
In its report submitted to the health ministry, the expert committee formed by the ministry to address the issue of faulty ASR hip replacement has noted that in the absence of any other model available, the maximum amount that can be granted as compensation should be at par with the maximum amount that is granted in compensation in cases of clinical trial-related death and permanent disability.
On financial compensation, the central committee will send its recommendations for consideration to the Drug Controller General of India (DCGI), who shall, in turn, pass an appropriate order.
Sources in the government claimed that while the data related to hip implant surgeries was available with hospitals, in this case traceability became an issue as hospitals said they did not have data, as it was not mandatory to maintain the records beyond three years of conducting a surgery. In this case, the surgeries were conducted before 2010. Delay in initiating the process of identification of patients has made the matter complex.
J&J’s subsidiary DePuy’s ASR Hip System was registered in India in October 2006 with a validity of three years. J&J’s Indian arm applied for a renewal of the license in May 2009 and obtained a fresh registration certificate in December 2009.
A J&J India spokesperson claimed that they had been fully transparent and furnished full information known to them at the time of making the renewal application in May 2009. The spokesperson added that the data showed that till mid-2010, their ASR Hip System was performing in line with other large diameter metal-on-metal monoblock and resurfacing hip devices. “Ultimately, after receiving the new 2010 UK National Joint Registry data, the company decided that it was in the best interests of patients to voluntarily recall the ASR Hip System worldwide. The ASR recall was voluntarily initiated by DePuy worldwide and in India simultaneously on August 24, 2010.”
Government sources claimed that not only the company did a voluntary recall of the device in 2010, after which it was not imported or sold in the country, but the government, too, on its part, had cancelled the import licence. “The company stopped manufacturing, importing and selling the device worldwide. The existing stock was recalled,” said an official.
J&J tried to clarify that a voluntary recall does not imply that the product was ‘faulty’. “It is also important to note that a voluntary recall doesn’t imply that the product is faulty nor does it imply that every patient who has received an ASR hip implant will necessarily have to undergo revision surgery. Indeed, ASR continues to function well for many patients in India and around the world,” the company spokesperson said.